Oral Anticoagulants in AFa,b A Brief History

NOACs Phase 3 Trials Spectrum of Stroke Risk in AF

NOACs Phase 3 Trials Dosing Strategies

NOACs Phase 3 Trials Mean CHADS2 Scores

NOACs Similar Half-Life, Different Daily Dosing?

NOACs in Clinical Practice Identifying Patients With Increased Bleeding Risk

NOACs Drug-drug Interactions

NOACs Monitoring Anticoagulant Effectsa

NOACs Considerations for Measuring Anticoagulant Activity

NOACs Preventing Excess Exposure

NOACs Antidotes and Reversal Agents

NOACs Antidotes and Reversal Agents (cont)

NOACs Addressing Patient Concernsa

NOACs Emerging Agents

Conclusions

Abbreviations

References

References (cont)

References (cont)

References (cont)

References (cont)